A faster-acting and more potent form of tissue plasminogen activator.
about
Aspect of thrombolytic therapy: a reviewTenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials.Massive pulmonary embolism in a Lebanese patient doubly heterozygous for MTHFR and Factor V Leiden presenting with syncope and treated with tenecteplase.The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade.Reteplase: a new thrombolytic for the treatment of acute myocardial infarction.Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activatorA phase III, randomized, double-blind, placebo-controlled study of tenecteplase for improvement of hemodialysis catheter function: TROPICS 3Thrombolytic drugs in acute myocardial infarction.A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction.Update on strategies to improve thrombolysis for acute myocardial infarction.Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation.Fibrinolytic and mechanical intervention trials in ST elevation acute myocardial infarction.Engineering the proteolytic specificity of activated protein C improves its pharmacological propertiesSafety and efficacy of tenecteplase in acute myocardial infarction.Retinal toxicity of intravitreal tenecteplase in the rabbitEarly statin use in ischemic stroke patients treated with recanalization therapy: retrospective observational study.Review of pharmacology and physiology in thrombolysis interventions.Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary EmbolismCrystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.Alteplase for acute ischemic stroke.Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding.Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1The Use of Recombinant Tissue Plasminogen Activator (rTPA) in The Treatment of Fibrinous Pleuropneumonia in Horses: 25 Cases (2007-2012)Plasmin therapy enhances mobilization of HPCs after G-CSFThe quest for arterial recanalization in acute ischemic stroke-the past, present and the future.Past, present and future of alteplase for acute ischemic stroke.Thrombolytics and myocardial infarction.Clinical controversies in thrombolytic therapy for the management of acute pulmonary embolism.Plasminogen activation and thrombolysis for ischemic stroke.Serine-proteases as plasminogen activators in terms of fibrinolysis.The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi.Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy.Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke.The evolution of recombinant thrombolytics: Current status and future directionsNovel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.Engineering of plasmin-resistant forms of streptokinase and their production in Bacillus subtilis: streptokinase with longer functional half-life.Late recanalisation beyond 24 hours is associated with worse outcome: an observational study.Studies of serpins unfold at a feverish pace.Amino acid domains control the circulatory residence time of primate acetylcholinesterases in rhesus macaques (Macaca mulatta).Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells.
P2860
Q26999262-D97F4148-D87B-489A-BFE6-D18EC9A31423Q30277030-6A32BC4E-DA02-45F3-83BC-3FBCF1A27158Q33153719-E0C35A24-B708-415F-911A-9152BD852815Q33568780-37B5115F-5B85-48F1-9271-CBA9389EB922Q33592435-9F48A237-C716-4CE5-AA9E-4C887724E5CEQ33605997-5CEE0FA8-1619-45AB-BB9B-E79087B01186Q33769956-958ADBD6-DF4E-4585-8C90-D7BF07FF7411Q33868351-A9287188-42B1-460D-8483-7BBB7443FFD8Q34159377-39DD9718-EA9B-48D0-9B31-C55938E5B60CQ34278839-A0ECA385-4D85-4361-8CCE-7ECBF1AF3832Q34589920-A172129C-00F9-4A16-83F5-D634C7EEB300Q34868156-ED763FAA-7302-41F3-AA5B-E78127D422F9Q34956516-81274A8D-FACA-478C-AD00-254E70A8609EQ35124719-B2D06E53-0981-40D4-98F4-F41CD72E3361Q35591883-A0FEBF0C-7E7F-4346-BBEC-F286138F9915Q35724997-FF9900B9-E64D-481F-8B15-89936F689438Q35882918-63001CAE-B3DF-4105-AA53-D26BB485D857Q35920702-94B9C89E-3FEA-41C1-8CF1-C30CA57EB72DQ36283476-75E4293E-AF40-45D6-BEE4-9E0E2D3FDD4CQ36484897-189E0CA0-99AB-4C8D-B882-64DBF382DE2EQ36510864-9DF18771-9ECE-4DBE-B7BB-AC493C57F458Q36515962-DD582A20-1737-452D-AF43-0CB37A326951Q36873495-8BFA246F-3B39-4BDB-B16B-41D19A3BD0E7Q36969719-02509384-3BF4-4E10-A7F6-542480054B8CQ37017597-2ED235BC-BA6B-4917-BA4D-863360B2ABC6Q37083630-85EB61AE-2EA4-494D-9336-726A33EA33B0Q37808766-1F5CE436-F01E-4B19-8DE5-DDB24D6C80ECQ37990838-192766D6-50C9-4E00-B5AC-BBA2F7B44677Q37998537-2AEDA585-CC72-4148-AA38-CF8DA9BBB6DCQ38024834-96F4BB67-C4FD-4FF5-8173-D9C5B2E6C006Q38209626-FC033D41-9949-4D72-A22D-C4A914DB2C82Q38527633-2E902A80-12F3-4549-9C20-F7D6FA234407Q38589822-834DEF57-DAFB-4355-B7CC-BD647173EBACQ38803641-26F9131A-CD93-47ED-9A27-D5CB886A02B7Q38917550-34A2FAC5-E743-4B5B-9075-084B4C1F9AC8Q39561202-B8ABD090-E865-4766-BA32-527D36D823F3Q39827256-479CB8AE-3F85-46F0-B97E-9BF1D27CC280Q40512829-612B4D4A-C9C1-4FC6-9766-1D7EDF28594CQ40623691-810F07D0-E53F-40C5-8FB2-7FF2E0F5D482Q40988590-DF2CE84A-E3AC-4AA7-A180-D9535B55C46C
P2860
A faster-acting and more potent form of tissue plasminogen activator.
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A faster-acting and more potent form of tissue plasminogen activator.
@ast
A faster-acting and more potent form of tissue plasminogen activator.
@en
type
label
A faster-acting and more potent form of tissue plasminogen activator.
@ast
A faster-acting and more potent form of tissue plasminogen activator.
@en
prefLabel
A faster-acting and more potent form of tissue plasminogen activator.
@ast
A faster-acting and more potent form of tissue plasminogen activator.
@en
P2093
P2860
P356
P1476
A faster-acting and more potent form of tissue plasminogen activator.
@en
P2093
P2860
P304
P356
10.1073/PNAS.91.9.3670
P407
P577
1994-04-01T00:00:00Z